Tim Smith

These data suggest more immediate benefits to alitretinoin, though ultraviolet therapy was shown to be cost-effective after 10 years of use.

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

In this cohort study, the drug survival rates of methotrexate, cyclosporine A, and dupilumab for adolescents with eczema were assessed along with reasons for discontinuation.

In this single center analysis, investigators highlighted results of dupilumab treatment after 3 years among patients with moderate-to-severe eczema.

This analysis aligns with previous research into dose optimization of biologics for psoriasis, affirming enhancement of outcomes without compromising patient safety.

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

This review compares the clinical and real-world outcomes of drugs such as mepolizumab versus drugs such as benralizumab for severe eosinophilic asthma.

This review provides an overview of current data on immune development and risk factors for preterm-born infant development of respiratory infections and wheezing.

These data on metabolic dysfunction-associated steatotic liver disease provide information on the economic burden among high-risk patients.

The Accure Laser System is indicated for long term treatment of patients known to have mild to severe inflammatory acne vulgaris.

This analysis may help identify at-risk patients of liver enzyme elevation following sustained virologic response among individuals with hepatitis C virus infection.

In this analysis, the investigators sought to assess the efficacy and safety of risankizumab compared to placebo for patients with palmoplantar psoriasis.

These data resulted from comparisons of the time to onset of action among various available systemic medications for those with plaque psoriasis.

This online diagnostic tool’s implementation among study participants led to increased confidence in making diagnoses of chronic plaque psoriasis.

This analysis indicates that patients with a history of a first melanoma are at risk for subsequent development of melanoma regardless of their race or their ethnicity.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

This research letter suggests that direct GOC may be considered efficacious for pediatric patients reporting non-severe symptoms which are skin-limited during a macrolide treatment.

While this analysis found social anhedonia may be a potential intervention for some, nonsocial cognition may have a significant role in social disconnection for those with schizophrenia.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

These findings highlight the underrepresentation of Black and Hispanic food allergy clinical trial participants and raise concerns about the generalizability of clinical research findings.

This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

In this latest edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news, we highlight updates from across therapeutic pipelines.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.